SGP (SpyGlass Pharma) EPS (Diluted): $-1.98 (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SGP SpyGlass Pharma Inc SGP
12 GF Score
Price $25.07
View Full Analysis

What is SpyGlass Pharma EPS (Diluted)?

SpyGlass Pharma SGP -0.59% 12 EPS (Diluted) is $-1.98 as of Jun. 2026. GuruFocus rates SGP with a GF Score™ of 12/100.

SpyGlass Pharma's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $-0.59. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.98.

SpyGlass Pharma's EPS (Basic) for the three months ended in Jun. 2026 was $-0.59. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.98.

SpyGlass Pharma's EPS without NRI for the three months ended in Jun. 2026 was $-0.59. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2026 was $-1.98.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

SpyGlass Pharma  (NAS:SGP) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

SpyGlass Pharma EPS (Diluted) Related Terms

SpyGlass Pharma EPS (Diluted) Historical Data

* Premium members only.

The historical data trend for SpyGlass Pharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SpyGlass Pharma EPS (Diluted) Chart

SpyGlass Pharma Annual Data
Trend Dec23 Dec24 Dec25
EPS (Diluted)
-1.17 -1.62 -1.25

SpyGlass Pharma Quarterly Data
Dec23 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EPS (Diluted) Get a 7-Day Free Trial -0.27 -0.31 -0.39 -0.69 -0.59

SGP vs RIGL, NGNE, OCS: EPS (Diluted) Comparison

For the Biotechnology subindustry, SpyGlass Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SpyGlass Pharma PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SpyGlass Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where SpyGlass Pharma's PE Ratio falls into.


SGP
12GF Score
SpyGlass Pharma Inc SGP
EPS (Diluted) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SpyGlass Pharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

SpyGlass Pharma's Diluted EPS for the fiscal year that ended in Dec. 2025 is calculated as

Diluted EPS (A: Dec. 2025 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-39.869-0)/31.911
=-1.25

SpyGlass Pharma's Diluted EPS for the quarter that ended in Jun. 2026 is calculated as

Diluted EPS (Q: Jun. 2026 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-19.864-0)/33.440
=-0.59

EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Diluted) →
What does a EPS (Diluted) of $-1.98 mean?
SpyGlass Pharma (SGP) has a EPS (Diluted) of $-1.98 as of Jun. 2026. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on SpyGlass Pharma and its competitors.
Is SpyGlass Pharma's EPS (Diluted) too high?
SpyGlass Pharma's current EPS (Diluted) is $-1.98. Overall, SpyGlass Pharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SpyGlass Pharma's EPS (Diluted) compare to RIGL and NGNE?
SpyGlass Pharma's EPS (Diluted) of $-1.98 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Diluted) for a Biotechnology company?
A good EPS (Diluted) depends on the Biotechnology industry context. However, EPS (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Diluted) mean?
A high EPS (Diluted) can signal that a stock is expensive relative to its fundamentals. Earnings per share (diluted) equals net income divided by the diluted average shares outstanding. View historical data on SpyGlass Pharma and its competitors. SpyGlass Pharma's current EPS (Diluted) is $-1.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SpyGlass Pharma stock overvalued right now?
SpyGlass Pharma (SGP) has a current EPS (Diluted) of $-1.98. The current EPS (Diluted) is $-1.98. SpyGlass Pharma's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Diluted) calculated?
EPS (Diluted) is calculated from a company's financial statements. For SpyGlass Pharma (SGP), the current EPS (Diluted) is $-1.98 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SpyGlass Pharma Business Description

Address 27061 Aliso Creek Road, Suite 100, Aliso Viejo, CA, USA, 92656
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
12GF Score

Get the complete analysis for SGP

EPS (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.07
Price